How does 300238's PS Ratio compare to its peers?

Insufficient data to answer this question

How does 300238's PS Ratio compare vs other companies in the CN Biotechs Industry?

Insufficient data to answer this question

What is 300238's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to answer this question

What is the Fair Price of 300238 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to answer this question

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to answer this question

Guanhao BiotechLtd (XSEC:300238) - Stock Price, News & Analysis

300238 Stock Overview

Develops, manufactures, and sells regenerative medicines and life sciences products primarily in China.

About the company

300238 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Guanhao Biotech Co.,Ltd. Competitors

Berry GenomicsLtd

SZSE:000710

CN¥3.5b

Landfar Bio-medicine

SZSE:000504

CN¥3.3b

Medicalsystem Biotechnology

SZSE:300439

CN¥4.4b

Wuhan Hiteck Biological PharmaLtd

SZSE:300683

CN¥4.2b

Price History & Performance

Summary of all time highs, changes and price drops for Guanhao BiotechLtd
Historical stock prices
Current Share Price	CN¥14.10
52 Week High	CN¥15.88
52 Week Low	CN¥7.48
Beta	0.75
11 Month Change	-7.24%
3 Month Change	52.93%
1 Year Change	-5.87%
33 Year Change	-15.82%
5 Year Change	-25.75%
Change since IPO	-65.93%

Recent updates

Shareholder Returns

	300238	CN Biotechs	CN Market
7D	6.8%	3.1%	3.9%
1Y	-5.9%	-16.2%	5.9%

Price Volatility

Is 300238's price volatile compared to industry and market?
300238 volatility
300238 Average Weekly Movement	14.2%
Biotechs Industry Average Movement	8.8%
Market Average Movement	7.8%
10% most volatile stocks in CN Market	12.0%
10% least volatile stocks in CN Market	5.3%

About the Company

Founded	Employees	CEO	Website
1999	535	Yongming Zhang	www.guanhaobio.com

Guanhao Biotech Co.,Ltd. develops, manufactures, and sells regenerative medicines and life sciences products primarily in China. It offers NormalGEN, a dura repair patch; GrandNeuro, a dura repair patch; ThormalGEN, a surgical patch; DermalGEN, a wound dressing product; IREAL breast patch; and Youvision corneal graft, as well as license in intraocular lenses.

Guanhao Biotech Co.,Ltd. Fundamentals Summary

How do Guanhao BiotechLtd's earnings and revenue compare to its market cap?
300238 fundamental statistics
Market cap	CN¥3.74b
Earnings (TTM)	CN¥17.57m
Revenue (TTM)	CN¥373.37m

212.8x

P/E Ratio

10.0x

P/S Ratio

Is 300238 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
300238 income statement (TTM)
Revenue	CN¥373.37m
Cost of Revenue	CN¥87.18m
Gross Profit	CN¥286.18m
Other Expenses	CN¥268.61m
Earnings	CN¥17.57m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.066
Gross Margin	76.65%
Net Profit Margin	4.71%
Debt/Equity Ratio	17.8%

How did 300238 perform over the long term?

See historical performance and comparison

300238 Stock Overview

Rewards

Risk Analysis

Guanhao Biotech Co.,Ltd. Competitors

SZSE:000710

CN¥3.5b

SZSE:000504

CN¥3.3b

SZSE:300439

CN¥4.4b

SZSE:300683

CN¥4.2b

Price History & Performance

Recent News & Updates

Beijing Century TianFu Venture Capital Centre (Limited Partnership) acquired 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. for CNY 85.4 million.

Third quarter 2024 earnings released: EPS: CN¥0.023 (vs CN¥0.04 in 3Q 2023)

Guanhao Biotech Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings released: EPS: CN¥0.027 (vs CN¥0.037 in 2Q 2023)

Guanhao Biotech Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Share price stability

Recent updates

Beijing Century TianFu Venture Capital Centre (Limited Partnership) acquired 2.89% stake in Guanhao Biotech Co.,Ltd. (SZSE:300238) from Guangzhou Zhiguang Biotechnology Co., Ltd. for CNY 85.4 million.

Third quarter 2024 earnings released: EPS: CN¥0.023 (vs CN¥0.04 in 3Q 2023)

Guanhao Biotech Co.,Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Second quarter 2024 earnings released: EPS: CN¥0.027 (vs CN¥0.037 in 2Q 2023)

Guanhao Biotech Co.,Ltd. to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: CN¥0.05 (vs CN¥0.08 in 1Q 2023)

Guanhao Biotech Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 26, 2024

Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 26, 2024

Full year 2023 earnings released: EPS: CN¥0.12 (vs CN¥1.16 loss in FY 2022)

Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 06, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: EPS: CN¥0.04 (vs CN¥0.046 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.037 (vs CN¥1.03 loss in 2Q 2022)

Guanhao Biotech Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Guanhao Biotech Co.,Ltd. Announces Management Appointments

Full year 2022 earnings released: CN¥1.16 loss per share (vs CN¥0.28 profit in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: EPS: CN¥0.046 (vs CN¥0.08 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥1.03 loss per share (vs CN¥0.08 profit in 2Q 2021)

High number of new and inexperienced directors

Guanhao Biotech Co.,Ltd., Annual General Meeting, May 18, 2022

First quarter 2022 earnings released: EPS: CN¥0.08 (vs CN¥0.07 in 1Q 2021)

Third quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.04 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.08 (vs CN¥0.062 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.07 (vs CN¥0.04 in 1Q 2020)

New 90-day low: CN¥18.95

Guanhao Biotech Co.,Ltd., Annual General Meeting, Mar 30, 2021

Full year 2020 earnings released: EPS CN¥0.18 (vs CN¥1.75 loss in FY 2019)

Guanhao Biotech Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 09, 2021

New 90-day low: CN¥22.15

New 90-day high: CN¥29.88

New 90-day high: CN¥29.30

New 90-day low: CN¥23.15

Third quarter earnings released

Guanhao Biotech Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Guanhao Biotech Co.,Ltd. (SZSE:300238) intends to acquire 31% stake in ZY Therapeutics Inc. from U.S.TIANYOU CAPITAL CORP for $3.1 million.

New 90-day high - CN¥38.39

Guanhao Biotech Co.,Ltd. to Report First Half, 2020 Results on Jul 21, 2020

Shareholder Returns

Price Volatility

About the Company

Guanhao Biotech Co.,Ltd. Fundamentals Summary

212.8x

10.0x

Earnings & Revenue